How Labcorp Holdings Inc. stacks up

LH · against 454 other Healthcare companies listed in US-listed

Growth

55/ 100

Below the middle of the pack.

Ranked #271 of 455 · scores higher than 40% of peers

Bars: peers in each 10-point band of the growth score

45 peers with a growth score of 50–59, including LH · Click a bar to see the companies

Why growth scores 55?

Weighted metrics compared with all Healthcare companies.

Its metrics sit close to the Healthcare norm.

Revenue growth is close to the peer norm. Revenue growth: 6.4% vs peer median 6.1%
3-year revenue growth is close to the peer norm. 3-year revenue growth: 6.5% vs peer median 5.8%
faster growth in earnings per share: stronger than 71% of peers. Earnings per share growth: 34.6% vs peer median 9.8%

Metric by metric

Position: dot = LH, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.

Metric	LH	Peer median	Better than	Weight
Revenue growthHigher is better · 475 reported	6.4%	11.0%	38%	33%
Earnings per share growthHigher is better · 171 reported	34.6%	21.2%	60%	33%
3-year revenue growthHigher is better · 433 reported	6.5%	11.0%	38%	33%

Ranking by growth score

Top 5 and the companies ranked around LH

Rank	Company	Market cap	Growth	Overall
1	Phathom Pharmaceuticals, Inc.PHAT · US-listed	411M USD	100	53
2	AnaptysBio, Inc.ANAB · US-listed	1.4B USD	99	73
2	CorMedix Inc.CRMD · US-listed	408M USD	99	81
2	ImmunityBio, Inc.IBRX · US-listed	8.5B USD	99	31
2	Insight Molecular Diagnostics Inc.IMDX · US-listed	81M USD	99	27
⋯
267	Cardinal Health, Inc.CAH · US-listed	62.0B USD	56	52
267	RadNet, Inc.RDNT · US-listed	6.1B USD	56

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score